TFMG
5年前
RLLVF to rally on Exclusivity Agreement with SOS Cannabis Inc
=====================
RLLVF (Relevium Technologies Inc.)
Current Price: $0.0592
Float: 122.64M
Website | Recent News
========================
Legal Cannabis is Expected to Grow 230%, to $31.3 Billion in 2022
Global spending on legal cannabis is expected to grow 230%, to $31.3 billion in 2022, compared to $9.5 billion in 2017, according to Arcview Market Research and BDS Analytics. The research suggests that most of that, nearly $23.4 billion, will be spent in the U.S. With more states voting for the legalization of marijuana and business interest sparking, that definitely makes sense.
Marijuana Regulation: The Facts
While Canada legalized marijuana in late 2018, it remains illegal under federal U.S. law and is still classified as a controlled substance without proven medical benefit, along with heroin and LSD. However, with some 30 states voting to make cannabis legal for medicinal use, recreational use, or both, marijuana regulation in the U.S. essentially is a hot mess.
30 states have approved the legalization of marijuana for medical or recreational use or both.
In 2018 alone, the following states voted in favor of marijuana legalization:
Michigan: Voters legalized marijuana use and cultivation for people over the age of 21 and authorized the commercial sale of marijuana through state-licensed retailers.
Missouri: Voters approved legalizing marijuana for medical purposes and allowing patients to cultivate plants at home.
Oklahoma: Voters approved legalizing marijuana for medical use.
Utah: Voters approved some use of marijuana for medical purposes.
Who are the Top Players in this Sector at the Moment
Canopy Growth Corp. ( CGC )
The first Canadian marijuana company, Canopy Growth Corp. is the world's largest publicly-traded weed company. The company owns and operates many brands, producing and marketing both medical and recreational strains. Tweed is one of the company's most popular brands, thanks to an association with rapper Snoop Dogg. For its 2019 fiscal year, it reported revenue of CAD 77.9 million or nearly $60 million.
In October 2017, Constellation Brands , the beverage giant, and maker of Corona beer bought a 9.9% stake in Canopy Growth. The deal offers both companies a chance at new product lines such as cannabis-infused beverages.
Aurora Cannabis Inc. ( ACB )
Another big Canadian pot company, Aurora Cannabis became even bigger in March by acquiring rival MedReleaf in a $250 million all-stock deal that was touted as the world's largest marijuana deal to date. Consolidating operations will help the new entity cut costs and gain efficiency. According to a press release, Aurora and MedReleaf together expect to produce over 570,000 kilograms per year of cannabis through nine facilities in Canada and two in Denmark.
Aurora debuted on the Canadian venture stock exchange (TSX) in October 2016 and trades in the U.S. on the NYSE.
Cronos Group Inc . ( CRON )
Nasdaq's first pot stock, Cronos Group is a Toronto-based cultivator of medical marijuana . In addition to Canada, Cronos serves international markets, shipping its products to Germany, building a facility in Israel, and starting a joint venture in Australia. Cronos Group does not have a presence in the U.S. due to the uncertainty in regulations.
As of its 2018 fiscal year, the company generated $7.3 million in revenue.
The Top Players Offer Little Upside Potential
Over the last 12 months, there has been tremendous hype on cannabis stocks. The widespread legalization in some states in the U.S. and all of Canada caused many stocks related to the pot industry to skyrocket, leaving little upside potential for investors late to the party.
However, there are still some juicy opportunities out there...
We've Found A Cannabis Stock That Still Has Plenty Of Room To Run
That company is Relevium Technologies, and it is publicly traded in three countries on three separate exchanges OTCQB: “RLLVF”, TSX.V: “RLV”, and Frankfurt: “6BX”.
Relevium Technologies is hitting on all cylinders from both a business and technical perspective, and they recently released some market friendly news that is sure to grab the attention of Wall Street.
The Company signed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which will provide pediatric customers with the ability to obtain free legal representation to seek reimbursement for the costs of medical cannabinoid therapy from different government agencies for the treatment of medical conditions for pediatric patients.
The partnership agreement will provide Relevium’s pediatric customers with access to an experienced legal and case management team, who will prepare the case file and seek retroactive and prospective reimbursement for parents of pediatric patients at no cost. The agreement provides Relevium with a unique advantage in terms of its business development strategy and first to market positioning in terms of pediatric applications.
Mr. Aurelio Useche, CEO of Relevium stated: “As we prepare to enter the pediatric endo-medicinal market in Canada with an initial ten (10) CannaKids® formulated products, not only are we providing parents with a natural alternative and/or health support mechanism, but now we are able to provide them with the ability to seek reimbursement from governmental agencies without any costs,” Mr. Useche stated further: “We are extremely happy to work with a team of caring legal professionals that can represent our customers in minimizing the financial burden of cannabinoid therapy.”
Maitre Robert Astell, President of SOSCannabis.com stated “We are delighted to welcome Relevium into our family of medicinal cannabinoid therapy suppliers. The focus and quest of Relevium in terms of pediatric patients is admirable and we look forward to onboarding parents into our fully-automated registration platform and to provide them with the state-of-the-art case management service in fulfilling their need for economic assistance in providing natural medicine to their children.”
Tracy Ryan, CEO of Cannakids® stated: “For years patients have struggled with the high expenses that come along with using cannabis as a medicine. Especially parents to sick children who often lose their jobs due to countless hospital stays and doctor’s appointments. This new opportunity for families is a major step in the right direction. We are elated that more will now have the opportunity to afford this powerful, non-toxic option that we have seen bring unimaginable relief to patients on a global scale.”
About Relevium Technologies
Relevium Technologies operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products.
Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Their specific focus is on products that promote overall health, nutraceuticals, fitness nutrition and cosmeceuticals. The company already has 25 products being sold on Amazon with more being planned.
Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as Walmart.com and Amazon.com.
The company’s product offering includes cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through their Bioganix®, Push & Pull System® and LeefyLyfe® brands with the objective of helping people lose weight, become healthier, happier, and most importantly achieve the results that our customers desire.
Bioganix®, founded in 2014, has some of the best-selling products in the Health and Personal Care category on Amazon, and a loyal customer base. The combination of online marketing with an emphasis on superior quality products backed by stringent scientific research and formulations, this has developed Bioganix® in becoming one of the leading dietary supplement brands online.
Push & Pull®, launched in 2019, is the first comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new brand targets a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.
LeefyLyfe® is their OTC cannabidiol Phyto formulated brand that combines the same trusted ingredients as those found in Bioganix® and Push & Pull® with the benefits of CBD . The company is currently waiting for the decision by the FDA to allow the sale of CBD as a supplement in order to release its products into the market.
Since 2017, Relevium’s OTC has grown its product offering and expanded its distribution channels to some of the largest online marketplaces such as eBay , Amazon and Walmart.com. Relevium will continue to innovate with the BioGanix brand, expand the product line and distribution channels to further drive growth.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
The company combines leading biopharma expertise, agricultural and logistic advantages of Colombia and trusted brand status with a clinically validation process for Phyto therapeutic medical products aimed at pediatric applications.
Biocannabix’ vertically integrated operations are located in key markets around the world: Canada, Colombia and Germany.
Scientific and Administrative Offices located in Montreal, Quebec
Cultivation and Extraction operations with an initial 20 hectares located in Cali , Colombia
Distribution and compliance partnership in Germany
The portfolio of Biocannabix brands include:
Cannakids®: Pediatric brand exclusive for the Canadian market
Relevium Senior®: Geriatric brand targeting inflammatory conditions including joints, heart and brain.
Relevium Kids®: Pediatric brand of Nutraceuticals and Oral Nutritional Supplements
Investment Highlights:
In 2017, the global wellness market reached $4.2T.
Global nutraceutical market to reach US$578.23B by 2025.
Vast distribution network through industry giants like Walmart and Amazon.
Building out 93,000-square-foot "Green Wave" cultivation and processing facility in Montreal, Quebec.
BioGanix generates approximately $1M in revenue per quarter.
47 SKUs developed for BioGanix to date.
Acquiring Cannakids’s IP , a leader in medical "Green Wave" patient research and pediatric and adult consumer product development.
Pending Sleipnir acquisition will initially bring in US$500K to Relevium’s topline revenue.
Partnership in place with HempCo Canada.
International expansion plans for all brands.
Relevium In the News
Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America
Earlier this month, RLVRelevium’s Biocannabix positioned itself as an important player in the Colombian medical cannabis market by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements.
On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS , a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia. With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World’s demand.
“This is a major strategic step in the development of our Phyto therapeutic biopharma business” stated Aurelio Useche, CEO of Relevium Technologies.
The Company’s subsidiary, Biocannabix Health Corporation, is a vertically integrated medical cannabis company with strategic positioning in three major markets: Canada, Latin America and Europe.
The company’s operations in Montreal allows Biocannabix to leverage leading edge scientific and research platforms as well as government incentives in the province of Quebec. The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali , Colombia
Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia.
KEY HIGHLIGHTS OF THE PARTNERSHIP WITH LIFELINE
Best in class partnership for international vertical integration.
Combination of Biocannabix focus on Pediatric Endo-Medicine with a large-scale operation with 150 years of sustainable, environmentally responsible and organic agricultural history
Located in Rozo, Valle del Cauca, in the heart of the sugar cane enclave seven minutes away from the international airport and 10 minutes away from Cali’s downtown core and a population of over 3M people
Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.
Full registration of 668 genetic strains with the ICA , the Instituto Colombiano Agropecuario.
Three licenses in progress including (1) extraction and manufacturing, (2) cultivation with THC and (3) non-psychoactive cultivation, all with scientific research, domestic sales and export modalities.
Strategic low-cost infrastructure that allows for an estimated stage two flower capacity of 170,000 Kg per year with an initial estimated cost of production 0.53$ per gram.
Development of an industrial scale extraction plant in the Pacific Free Zone, a private industrial park located minutes away from the cultivation project. The free zone offers the benefits of the free regime and seeks to promote and develop the process of industrialization of goods, the productive chain and the provision of services, as well as strengthen the competitiveness of its users and customers by taking advantage of the generated opportunities from international trade and bilateral agreements signed by Colombia.
Genetics laboratory and agronomic research in the BioParque del Pacifico located in the campus of the International Center for Tropical Agriculture (CIAT) and the Colombian Corporation for agricultural research (Agrosavia).
STRATEGIC FIT FOR GLOBAL SUPPLY AND VERTICAL INTEGRATION
Relevium’s Bio-Pharma arm, Biocannabix, is focused in developing, marketing and selling endo-medicinal formulations on Nutraceuticals and Medical foods aimed primarily to pediatrics. An essential component of the strategy of delivering safe, 100% auditable medicine for pediatric patients is to ensure total control over the genetics, the cultivation and the processing of extracts. The partnership with Lifeline ensures a 100% organically grown product with access to over 600 registered genetic strains, the buildout of an EU GMP extraction facility in the Pacific Free Zone and the ability to trace and fully audit the process from seed to medicine through blockchain technology.
The strict regulation of the Colombian legal regime for cannabis only allow for the export of extracts and finished goods and we aim to service international demand for organically sourced medical cannabis extracts for LATAM, Europe and eventually the Asian continent.
LOCAL MARKET THAT IS READY TO ADOPT ENDO-MEDICINAL FORMULATIONS
Traditional remedies and natural medicine are an integral part of Colombian culture and with a fast-growing middle class and entrepreneurial nature, this market with a population of over 49 million is moving quickly to adopt cannabinoid therapy. Lifeline, through Biocannabix pediatric formulations, is poised to successfully obtain a significant market share of the local market.
TRANSACTION DETAILS
Under the terms of the binding agreement, Biocannabix will acquire 100% of the shares on Lifeline Pharma SAS by investing an initial US$850,000 to be deployed during stage one of the projects. The initial investment is comprised of US$125,000 at signing, US$125,000 upon the grant of the initial licenses and a commitment to deploy funds totalling US$600,000 over the next seven months. As part of the transaction, Biocannabix Health Corporation will issue US$3,650,000 in shares representing approximately 41% of the shares outstanding of the wholly owned subsidiary.
In the event of a major transaction including a sale or a public offering, the shareholders of Lifeline Pharma will also receive an additional US$1.5 million to be settled in shares of Biocannabix or in cash.
Aurelio Useche, CEO of Relevium stated: “The acquisition and partnership with Lifeline Pharma SAS in Colombia represents the single most important development to date for Relevium, our team and our shareholders. This is the culmination of months of strategic re-alignment, negotiations and a lot of hard work by our team and the key stakeholders of Lifeline”. Mr. Useche added:” We are very pleased and proud to partner with the amazing team of Lifeline, including Oscar LIbreros CEO and Hossein Shadanlou COO and look forward to work together to execute on the common mission of providing safe, organically sourced and fully auditable endo-medicinal products for pediatric applications”
Oscar LIbreros, CEO of Lifeline Pharma SAS stated: “With over 150 years of tradition in organic farming and our objective to provide the best medical cannabis extracts and products, we are happy (THRILLED) to join forces and merge with Biocannabix Health Corporation in Canada. We look forward to delivering real value through the disciplined deployment of our operational strategy from Colombia to the world”
Cannabis Cultivation and Extraction Potentially Costs 80% Less in Latin America
With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World's demand.
The region boasts exceptional climatic conditions, with lots of sunshine and good rainfall. This coupled with acres and acres of arable land, could make the LATAM region the global leaders in cannabis production.
In addition to the above, the price of labor is exceptionally cheap when compared to it's European and North American counterparts. Combined, it is estimated that LATAM will be able to produce cannabis – in commercial quantities – for nearly 80% less than the rest of the world. That's a pretty big advantage.
The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
The Bottom Line
RLLVF deserves your immediate attention
We suggest that you add this rapidly growing microcap cannabis company to the top of your watch-list, as these triggered technical indicators and company news could bring serious interest to this stock.
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated three thousand dollars by MJ Capital LLC for an investor relations advertising marketing campaign w/ 2000 TradingView™ views for RLLVF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
TFMG
5年前
RLLVF could run +78% (or more) in share price today!
=====================
RLLVF (Relevium Technologies Inc.)
Alert Price: $0.06
Float: 122.64M
Website | Recent News
========================
The global nutraceutical market is estimated to be over $200 billion USD and is expected to reach $300 billion by the end of 2023.
Growing awareness regarding the consumption of healthy foods has resulted in increased demand for nutraceuticals in the U.S. The European market is driven by a steady innovation of high-performance natural ingredients used in nutraceuticals. Increasing adoption of e-commerce and growing consumer awareness through social media are further likely to augment the demand for nutraceuticals over the forecast period.
The market has witnessed an increased focus on the ingredients used for manufacturing nutraceuticals. The demand for natural products is expected to grow at a rapid pace over the next eight years as consumers perceive these products to be healthier and more effective as compared to synthetic products.
We have identified a rapidly growing micro-cap company that is already well positioned to capitalize on this multi-billion dollar market.
That company is Relevium Technologies, and it is publicly traded in three countries on three separate exchanges OTCQB: “RLLVF”, TSX.V: “RLV”, and Frankfurt: “6BX”.
About Relevium Technologies
Relevium Technologies operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products.
Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Their specific focus is on products that promote overall health, nutraceuticals, fitness nutrition and cosmeceuticals. The company already has 25 products being sold on Amazon with more being planned.
Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as Walmart.com and Amazon.com.
The company’s product offering includes cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through their Bioganix®, Push & Pull System® and LeefyLyfe® brands with the objective of helping people lose weight, become healthier, happier, and most importantly achieve the results that our customers desire.
Bioganix®, founded in 2014, has some of the best-selling products in the Health and Personal Care category on Amazon, and a loyal customer base. The combination of online marketing with an emphasis on superior quality products backed by stringent scientific research and formulations, this has developed Bioganix® in becoming one of the leading dietary supplement brands online.
Push & Pull®, launched in 2019, is the first comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new brand targets a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.
LeefyLyfe® is their OTC cannabidiol Phyto formulated brand that combines the same trusted ingredients as those found in Bioganix® and Push & Pull® with the benefits of CBD . The company is currently waiting for the decision by the FDA to allow the sale of CBD as a supplement in order to release its products into the market.
Since 2017, Relevium’s OTC has grown its product offering and expanded its distribution channels to some of the largest online marketplaces such as eBay , Amazon and Walmart.com. Relevium will continue to innovate with the BioGanix brand, expand the product line and distribution channels to further drive growth.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
The company combines leading biopharma expertise, agricultural and logistic advantages of Colombia and trusted brand status with a clinically validation process for Phyto therapeutic medical products aimed at pediatric applications.
Biocannabix’ vertically integrated operations are located in key markets around the world: Canada, Colombia and Germany.
Scientific and Administrative Offices located in Montreal, Quebec
Cultivation and Extraction operations with an initial 20 hectares located in Cali , Colombia
Distribution and compliance partnership in Germany
The portfolio of Biocannabix brands include:
Cannakids®: Pediatric brand exclusive for the Canadian market
Relevium Senior®: Geriatric brand targeting inflammatory conditions including joints, heart and brain.
Relevium Kids®: Pediatric brand of Nutraceuticals and Oral Nutritional Supplements
Investment Highlights:
In 2017, the global wellness market reached $4.2T.
Global nutraceutical market to reach US$578.23B by 2025.
Vast distribution network through industry giants like Walmart and Amazon.
Building out 93,000-square-foot "Green Wave" cultivation and processing facility in Montreal, Quebec.
BioGanix generates approximately $1M in revenue per quarter.
47 SKUs developed for BioGanix to date.
Acquiring Cannakids’s IP , a leader in medical "Green Wave" patient research and pediatric and adult consumer product development.
Pending Sleipnir acquisition will initially bring in US$500K to Relevium’s topline revenue.
Partnership in place with HempCo Canada.
International expansion plans for all brands.
Recent Developments for Relevium
Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America
Earlier this month, RLVRelevium’s Biocannabix positioned itself as an important player in the Colombian medical cannabis market by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements.
On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS , a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia. With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World’s demand.
“This is a major strategic step in the development of our Phyto therapeutic biopharma business” stated Aurelio Useche, CEO of Relevium Technologies.
The Company’s subsidiary, Biocannabix Health Corporation, is a vertically integrated medical cannabis company with strategic positioning in three major markets: Canada, Latin America and Europe.
The company’s operations in Montreal allows Biocannabix to leverage leading edge scientific and research platforms as well as government incentives in the province of Quebec. The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali , Colombia
Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia.
KEY HIGHLIGHTS OF THE PARTNERSHIP WITH LIFELINE
Best in class partnership for international vertical integration.
Combination of Biocannabix focus on Pediatric Endo-Medicine with a large-scale operation with 150 years of sustainable, environmentally responsible and organic agricultural history
Located in Rozo, Valle del Cauca, in the heart of the sugar cane enclave seven minutes away from the international airport and 10 minutes away from Cali’s downtown core and a population of over 3M people
Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.
Full registration of 668 genetic strains with the ICA , the Instituto Colombiano Agropecuario.
Three licenses in progress including (1) extraction and manufacturing, (2) cultivation with THC and (3) non-psychoactive cultivation, all with scientific research, domestic sales and export modalities.
Strategic low-cost infrastructure that allows for an estimated stage two flower capacity of 170,000 Kg per year with an initial estimated cost of production 0.53$ per gram.
Development of an industrial scale extraction plant in the Pacific Free Zone, a private industrial park located minutes away from the cultivation project. The free zone offers the benefits of the free regime and seeks to promote and develop the process of industrialization of goods, the productive chain and the provision of services, as well as strengthen the competitiveness of its users and customers by taking advantage of the generated opportunities from international trade and bilateral agreements signed by Colombia.
Genetics laboratory and agronomic research in the BioParque del Pacifico located in the campus of the International Center for Tropical Agriculture (CIAT) and the Colombian Corporation for agricultural research (Agrosavia).
STRATEGIC FIT FOR GLOBAL SUPPLY AND VERTICAL INTEGRATION
Relevium’s Bio-Pharma arm, Biocannabix, is focused in developing, marketing and selling endo-medicinal formulations on Nutraceuticals and Medical foods aimed primarily to pediatrics. An essential component of the strategy of delivering safe, 100% auditable medicine for pediatric patients is to ensure total control over the genetics, the cultivation and the processing of extracts. The partnership with Lifeline ensures a 100% organically grown product with access to over 600 registered genetic strains, the buildout of an EU GMP extraction facility in the Pacific Free Zone and the ability to trace and fully audit the process from seed to medicine through blockchain technology.
The strict regulation of the Colombian legal regime for cannabis only allow for the export of extracts and finished goods and we aim to service international demand for organically sourced medical cannabis extracts for LATAM, Europe and eventually the Asian continent.
LOCAL MARKET THAT IS READY TO ADOPT ENDO-MEDICINAL FORMULATIONS
Traditional remedies and natural medicine are an integral part of Colombian culture and with a fast-growing middle class and entrepreneurial nature, this market with a population of over 49 million is moving quickly to adopt cannabinoid therapy. Lifeline, through Biocannabix pediatric formulations, is poised to successfully obtain a significant market share of the local market.
TRANSACTION DETAILS
Under the terms of the binding agreement, Biocannabix will acquire 100% of the shares on Lifeline Pharma SAS by investing an initial US$850,000 to be deployed during stage one of the projects. The initial investment is comprised of US$125,000 at signing, US$125,000 upon the grant of the initial licenses and a commitment to deploy funds totalling US$600,000 over the next seven months. As part of the transaction, Biocannabix Health Corporation will issue US$3,650,000 in shares representing approximately 41% of the shares outstanding of the wholly owned subsidiary.
In the event of a major transaction including a sale or a public offering, the shareholders of Lifeline Pharma will also receive an additional US$1.5 million to be settled in shares of Biocannabix or in cash.
Aurelio Useche, CEO of Relevium stated: “The acquisition and partnership with Lifeline Pharma SAS in Colombia represents the single most important development to date for Relevium, our team and our shareholders. This is the culmination of months of strategic re-alignment, negotiations and a lot of hard work by our team and the key stakeholders of Lifeline”. Mr. Useche added:” We are very pleased and proud to partner with the amazing team of Lifeline, including Oscar LIbreros CEO and Hossein Shadanlou COO and look forward to work together to execute on the common mission of providing safe, organically sourced and fully auditable endo-medicinal products for pediatric applications”
Oscar LIbreros, CEO of Lifeline Pharma SAS stated: “With over 150 years of tradition in organic farming and our objective to provide the best medical cannabis extracts and products, we are happy (THRILLED) to join forces and merge with Biocannabix Health Corporation in Canada. We look forward to delivering real value through the disciplined deployment of our operational strategy from Colombia to the world”
Cannabis Cultivation and Extraction Potentially Costs 80% Less in Latin America
With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World's demand.
The region boasts exceptional climatic conditions, with lots of sunshine and good rainfall. This coupled with acres and acres of arable land, could make the LATAM region the global leaders in cannabis production.
In addition to the above, the price of labor is exceptionally cheap when compared to it's European and North American counterparts. Combined, it is estimated that LATAM will be able to produce cannabis – in commercial quantities – for nearly 80% less than the rest of the world. That's a pretty big advantage.
The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
We See the Potential For a +78% Move From Here
We've done our very own chart analysis, and we see the potential for a move of +78% from here.
Bullish Technical Indicators:
Well defined price channel established with respected trendlines .
Bottom hit and reversed on the daily candle.
Accumulative volume spikes.
Bounce off well defined trendline . Ready to trend higher.
Increased volume .
The Bottom Line
RLLVF deserves your immediate attention
We suggest that you add this rapidly growing micro-cap to the top of your watch-list, as these triggered technical indicators and company news could bring serious interest to this stock.
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated three thousand dollars by STM LLC for an investor relations advertising marketing campaign w/ 2000 TradingView™ views for RLLVF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
TFMG
5年前
RLLVF could run +78% (or more) in share price today!
=====================
RLLVF (Relevium Technologies Inc.)
Alert Price: $0.06
Float: 122.64M
Website | Recent News
========================
The global nutraceutical market is estimated to be over $200 billion USD and is expected to reach $300 billion by the end of 2023.
Growing awareness regarding the consumption of healthy foods has resulted in increased demand for nutraceuticals in the U.S. The European market is driven by a steady innovation of high-performance natural ingredients used in nutraceuticals. Increasing adoption of e-commerce and growing consumer awareness through social media are further likely to augment the demand for nutraceuticals over the forecast period.
The market has witnessed an increased focus on the ingredients used for manufacturing nutraceuticals. The demand for natural products is expected to grow at a rapid pace over the next eight years as consumers perceive these products to be healthier and more effective as compared to synthetic products.
We have identified a rapidly growing micro-cap company that is already well positioned to capitalize on this multi-billion dollar market.
That company is Relevium Technologies, and it is publicly traded in three countries on three separate exchanges OTCQB: “RLLVF”, TSX.V: “RLV”, and Frankfurt: “6BX”.
About Relevium Technologies
Relevium Technologies operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products.
Relevium’s products are part of the $3.72 trillion dollar global wellness industry — one of the fastest growing worldwide markets. Their specific focus is on products that promote overall health, nutraceuticals, fitness nutrition and cosmeceuticals. The company already has 25 products being sold on Amazon with more being planned.
Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including such as Walmart.com and Amazon.com.
The company’s product offering includes cutting-edge line of weight-loss, anti-inflammatory, heart, vision, beauty and fitness supplements sold through their Bioganix®, Push & Pull System® and LeefyLyfe® brands with the objective of helping people lose weight, become healthier, happier, and most importantly achieve the results that our customers desire.
Bioganix®, founded in 2014, has some of the best-selling products in the Health and Personal Care category on Amazon, and a loyal customer base. The combination of online marketing with an emphasis on superior quality products backed by stringent scientific research and formulations, this has developed Bioganix® in becoming one of the leading dietary supplement brands online.
Push & Pull®, launched in 2019, is the first comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new brand targets a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.
LeefyLyfe® is their OTC cannabidiol Phyto formulated brand that combines the same trusted ingredients as those found in Bioganix® and Push & Pull® with the benefits of CBD . The company is currently waiting for the decision by the FDA to allow the sale of CBD as a supplement in order to release its products into the market.
Since 2017, Relevium’s OTC has grown its product offering and expanded its distribution channels to some of the largest online marketplaces such as eBay , Amazon and Walmart.com. Relevium will continue to innovate with the BioGanix brand, expand the product line and distribution channels to further drive growth.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.
The company combines leading biopharma expertise, agricultural and logistic advantages of Colombia and trusted brand status with a clinically validation process for Phyto therapeutic medical products aimed at pediatric applications.
Biocannabix’ vertically integrated operations are located in key markets around the world: Canada, Colombia and Germany.
Scientific and Administrative Offices located in Montreal, Quebec
Cultivation and Extraction operations with an initial 20 hectares located in Cali , Colombia
Distribution and compliance partnership in Germany
The portfolio of Biocannabix brands include:
Cannakids®: Pediatric brand exclusive for the Canadian market
Relevium Senior®: Geriatric brand targeting inflammatory conditions including joints, heart and brain.
Relevium Kids®: Pediatric brand of Nutraceuticals and Oral Nutritional Supplements
Investment Highlights:
In 2017, the global wellness market reached $4.2T.
Global nutraceutical market to reach US$578.23B by 2025.
Vast distribution network through industry giants like Walmart and Amazon.
Building out 93,000-square-foot "Green Wave" cultivation and processing facility in Montreal, Quebec.
BioGanix generates approximately $1M in revenue per quarter.
47 SKUs developed for BioGanix to date.
Acquiring Cannakids’s IP , a leader in medical "Green Wave" patient research and pediatric and adult consumer product development.
Pending Sleipnir acquisition will initially bring in US$500K to Relevium’s topline revenue.
Partnership in place with HempCo Canada.
International expansion plans for all brands.
Recent Developments for Relevium
Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America
Earlier this month, RLVRelevium’s Biocannabix positioned itself as an important player in the Colombian medical cannabis market by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements.
On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS , a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia. With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World’s demand.
“This is a major strategic step in the development of our Phyto therapeutic biopharma business” stated Aurelio Useche, CEO of Relevium Technologies.
The Company’s subsidiary, Biocannabix Health Corporation, is a vertically integrated medical cannabis company with strategic positioning in three major markets: Canada, Latin America and Europe.
The company’s operations in Montreal allows Biocannabix to leverage leading edge scientific and research platforms as well as government incentives in the province of Quebec. The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali , Colombia
Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS , a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia.
KEY HIGHLIGHTS OF THE PARTNERSHIP WITH LIFELINE
Best in class partnership for international vertical integration.
Combination of Biocannabix focus on Pediatric Endo-Medicine with a large-scale operation with 150 years of sustainable, environmentally responsible and organic agricultural history
Located in Rozo, Valle del Cauca, in the heart of the sugar cane enclave seven minutes away from the international airport and 10 minutes away from Cali’s downtown core and a population of over 3M people
Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.
Full registration of 668 genetic strains with the ICA , the Instituto Colombiano Agropecuario.
Three licenses in progress including (1) extraction and manufacturing, (2) cultivation with THC and (3) non-psychoactive cultivation, all with scientific research, domestic sales and export modalities.
Strategic low-cost infrastructure that allows for an estimated stage two flower capacity of 170,000 Kg per year with an initial estimated cost of production 0.53$ per gram.
Development of an industrial scale extraction plant in the Pacific Free Zone, a private industrial park located minutes away from the cultivation project. The free zone offers the benefits of the free regime and seeks to promote and develop the process of industrialization of goods, the productive chain and the provision of services, as well as strengthen the competitiveness of its users and customers by taking advantage of the generated opportunities from international trade and bilateral agreements signed by Colombia.
Genetics laboratory and agronomic research in the BioParque del Pacifico located in the campus of the International Center for Tropical Agriculture (CIAT) and the Colombian Corporation for agricultural research (Agrosavia).
STRATEGIC FIT FOR GLOBAL SUPPLY AND VERTICAL INTEGRATION
Relevium’s Bio-Pharma arm, Biocannabix, is focused in developing, marketing and selling endo-medicinal formulations on Nutraceuticals and Medical foods aimed primarily to pediatrics. An essential component of the strategy of delivering safe, 100% auditable medicine for pediatric patients is to ensure total control over the genetics, the cultivation and the processing of extracts. The partnership with Lifeline ensures a 100% organically grown product with access to over 600 registered genetic strains, the buildout of an EU GMP extraction facility in the Pacific Free Zone and the ability to trace and fully audit the process from seed to medicine through blockchain technology.
The strict regulation of the Colombian legal regime for cannabis only allow for the export of extracts and finished goods and we aim to service international demand for organically sourced medical cannabis extracts for LATAM, Europe and eventually the Asian continent.
LOCAL MARKET THAT IS READY TO ADOPT ENDO-MEDICINAL FORMULATIONS
Traditional remedies and natural medicine are an integral part of Colombian culture and with a fast-growing middle class and entrepreneurial nature, this market with a population of over 49 million is moving quickly to adopt cannabinoid therapy. Lifeline, through Biocannabix pediatric formulations, is poised to successfully obtain a significant market share of the local market.
TRANSACTION DETAILS
Under the terms of the binding agreement, Biocannabix will acquire 100% of the shares on Lifeline Pharma SAS by investing an initial US$850,000 to be deployed during stage one of the projects. The initial investment is comprised of US$125,000 at signing, US$125,000 upon the grant of the initial licenses and a commitment to deploy funds totalling US$600,000 over the next seven months. As part of the transaction, Biocannabix Health Corporation will issue US$3,650,000 in shares representing approximately 41% of the shares outstanding of the wholly owned subsidiary.
In the event of a major transaction including a sale or a public offering, the shareholders of Lifeline Pharma will also receive an additional US$1.5 million to be settled in shares of Biocannabix or in cash.
Aurelio Useche, CEO of Relevium stated: “The acquisition and partnership with Lifeline Pharma SAS in Colombia represents the single most important development to date for Relevium, our team and our shareholders. This is the culmination of months of strategic re-alignment, negotiations and a lot of hard work by our team and the key stakeholders of Lifeline”. Mr. Useche added:” We are very pleased and proud to partner with the amazing team of Lifeline, including Oscar LIbreros CEO and Hossein Shadanlou COO and look forward to work together to execute on the common mission of providing safe, organically sourced and fully auditable endo-medicinal products for pediatric applications”
Oscar LIbreros, CEO of Lifeline Pharma SAS stated: “With over 150 years of tradition in organic farming and our objective to provide the best medical cannabis extracts and products, we are happy (THRILLED) to join forces and merge with Biocannabix Health Corporation in Canada. We look forward to delivering real value through the disciplined deployment of our operational strategy from Colombia to the world”
Cannabis Cultivation and Extraction Potentially Costs 80% Less in Latin America
With a much lower cost of production, a robust commercial and legal framework and a culture that is open to Phyto therapeutic medicine, Colombia is quickly becoming a global center of medical cannabis supply and it is forecasted that the Country will be looking to supply as much as 44% of the World's demand.
The region boasts exceptional climatic conditions, with lots of sunshine and good rainfall. This coupled with acres and acres of arable land, could make the LATAM region the global leaders in cannabis production.
In addition to the above, the price of labor is exceptionally cheap when compared to it's European and North American counterparts. Combined, it is estimated that LATAM will be able to produce cannabis – in commercial quantities – for nearly 80% less than the rest of the world. That's a pretty big advantage.
The recent acquisition of LifeLine in Colombia allows the company to leverage lower costs of cultivation and processing as well as to manage its own genetics for the production of targeted Phyto therapeutic formulations. Colombia, Canada and Germany combined are central to the clinical validation program for the ENS and ONS products that will be offered in all three markets.
We See the Potential For a +78% Move From Here
We've done our very own chart analysis, and we see the potential for a move of +78% from here.
Bullish Technical Indicators:
Well defined price channel established with respected trendlines .
Bottom hit and reversed on the daily candle.
Accumulative volume spikes.
Bounce off well defined trendline . Ready to trend higher.
Increased volume .
The Bottom Line
RLLVF deserves your immediate attention
We suggest that you add this rapidly growing micro-cap to the top of your watch-list, as these triggered technical indicators and company news could bring serious interest to this stock.
Best Regards,
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated three thousand dollars by STM LLC for an investor relations advertising marketing campaign w/ 2000 TradingView™ views for RLLVF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
JohnCM
6年前
RELEVIUM TECHNOLOGIES INC.
MANAGEMENT’S DISCUSSION & ANALYSIS
May 30, 2018
For the Three and Nine-Month Period Ended March 31, 2018 and 2017
MANAGEMENT DISCUSSION AND ANALYSIS
OVERVIEW
Relevium Technologies Inc., (the "Company") was incorporated under the Canada Business
Corporations Act on July 19, 2012 and its registered head office is located at 1000 Sherbrooke
St. West, Suite 2700, Montreal, Quebec, Canada.
The principal business of the Company is the identification, evaluation, acquisition and
operation of entrepreneurial brands and businesses in the Health and Wellness markets with a
strong focus on E-Commerce. The Company is a publicly traded corporation trading under ticker
symbol "RLV" on the TSX Venture Exchange and "6BX" on the Open Market Segment of the
Frankfurt Stock Exchange.
Background
The Company was incorporated on July 19, 2012 as Ovid Capital Inc. and was classified as a
Capital Pool Company (“CPC”) as defined by Policy 2.4 of the TSX Venture Exchange (the
“Exchange”).
On August 7, 2015, the Company completed its Qualifying Transaction (“QT”) and on August 13,
2015 changed its name to Bioflex Technologies Inc. and began trading under the symbol “BFT”
in the TSX Venture Exchange. Under the terms of the QT, the Company acquired certain assets
from Bioflex Medical Magnets and ITECH Medical, including the patents and trademarks with
the objective of developing a new product line of wearable braces to improve pain and swelling
arising primarily from musculoskeletal injuries.
On October 29, 2015, the Company announced a corporate rebrand and name change to
Relevium Technologies Inc. to better reflect a broader approach to its Health and Wellness
corporate strategy. On December 17, 2015, the Company was rebranded to Relevium
Technologies Inc. as approved by shareholders’ vote at the Company’s scheduled annual
general meeting.
For the Three and Nine-Month Period Ended March 31, 2018 and 2017
The Company is engaged in the identification, acquisition and development of entrepreneurial
consumer brands in the Health and Wellness space, including Nutraceuticals, Nutrition and
consumables that support overall fitness and wellbeing.
CORPORATE HIGHLIGHTS FOR THE REPORTING PERIOD
During the nine-month period ended March 31, 2017 (the “Reporting Period”), the Company
focused on the integration of BioGanix, evaluation of the product offering, brand repositioning
and developing a growth strategy including accessing new online marketplaces, international
expansion investing into technology, new talent and management platforms. The Company is
guided by the objective of increasing the existing brand equity of the assets acquired.
The following section describes the major highlights of the Company for the reporting period:
Core Business
The Company’s wholly-owned subsidiary, BGX E-Health LLC, operates all the online assets that
support the operations and sales of its Bioganix® brand of nutraceutical and wellness consumer
products with quality formulations at competitive prices, with a focus on providing an overall
awesome customer experience. All BioGanix products are produced by tested and verified by
GMP Certified and FDA inspected facilities across the USA.
During the reporting period the company has invested a large portion of its resources to
reposition the Bioganix® brand and prepare it for expansion internationally. As at March 31,
2018, the company offered 38 dietary supplement products and was preparing to launch an
additional 12 products in fiscal Q4. The Bioganix® brand offers a complete line of products,
from trending weight loss to proven health supporting supplements including digestive health,
heart health, brain health, blood sugar, as well as anti-aging supplements. Bioganix® is sold in
the USA primarily through amazon and through its website https://www.bioganix.com.
Bioganix® is currently not sold in Canada and it is expected that the company will apply to the
Natural and Non-prescription Health Products Directorate (NNHPD) to seek approval for sale in
Canada.
During the three-month period ended March 31, 2018, the company’s core business:
1. Initiated a market test for the eventual launch of a complete Aloe Vera based health
support products and cosmetics
2. Revealed a new brand architecture for Bioganix®
3. Conducted the initial joint-launch of Planet Hemp with HEMPCO
4. Established its presence for the European marketplace in partnership with Amazon
During the three months ended March 31, 2018 the company reported $1,036,176 in revenues
from its Bioganix® brand with a gross profit margin of 56% or $575,495. During the nine-month
reporting period of fiscal year ending June 30, 2018, the Bioganix® brand reported revenues of
$3,157,644 and a gross profit margin of 57% or $1,806,515. Bioganix® is a stepping stone in the
Company’s strategic plan to build a portfolio of e-commerce brands in the Health and Wellness
space. In addition to expanding the current product offering through the introduction of new
products, the Company also plans to launch parallel brands under BGX E-Health to target
specific segments.
New Business
During the nine-month period ended March 31, 2018, the Company was able to execute several
exclusivity agreements aimed at securing exclusive products, formulations and/or intellectual
property in order to build brand equity.
The company executed exclusive deals that allows the company to introduce Hemp Products,
Aloe Vera products, Omega 7 formulations and Pet supplements.
The transaction with Hempco aims at collaborating with a Canadian-based leader in the Hemp
business to develop and launch hemp-based products. The Company executed an initial launch
of several HEMP products and is now targeting the other markets and platforms including the
UK.
The transaction with Tersus Life Sciences aims at licensing the exclusive rights to launch a series
of specialized and unique Omega 7 Provinal nutraceuticals, which will be unique in the market.
The companies have developed two formulations, which are expected to go into production in
the month of May and be online in June.
The cooperation between the Company, Salvenia Nutrition and Biodevas Laboratories will lead
to the development of a line of Phytoceuticals for companion pets and complement a wider
product line planned for launching this year. The development of the pet nutrition products are
expected to take place in the fall of this year.
Technology Development
During the reporting period, the Company initiated several projects aimed at utilizing artificial
intelligence and blockchain in its e-retail strategy.
On January 11, 2018 the Company announced a JV with Quantomic LLC with the objective to
pool resources to use the Tagspire technology, integrate blockchain and pursue a token
offering. During the reporting quarter, the companies continued to cooperate to develop the
right strategy and fit for the technology within the context of blockchain.
On March 5, 2018, the Company engaged blockchain expert Didier Martin as the company’s
Lead Blockchain Expert. The company remains committed to integrate AI and Blockchain
technology to address value added opportunities for its current business and for the future
scalability of its M&A activities.
Mergers and Acquisitions
The Company remains active in reviewing and sustaining the incoming deal flow for M&A
transactions. However, management is of the opinion that the company’s equity remains
undervalued and cannot currently sustain dilution at these levels.
During the three-month period ended March 31, 2018 the company reviewed three
opportunities for acquisitions and decided to postpone negotiations until such time as deemed
accretive and beneficial to the company and its shareholders.
About the Nutraceutical Marketplace
Nutraceuticals are nutritional supplements derived from natural sources that compliment
progressive health and wellness programs. Nutraceuticals play a significant role in preventive
health and therefore are an area of strategic focus in terms of our business strategy.
Relevium’s initial focus will be on building e-retail assets and expanding product offerings by
introducing new formulations to support Health and Wellness. Investment in this market is
supported by industry projections for growth in a market that is estimated to reach USD 38.7
Billion by 2020.
The market for nutraceuticals is highly competitive. Direct competition to Relevium consists of
publicly and privately-owned companies, which tend to be highly fragmented in terms of both
geographic market coverage and product categories. In many of the products offered through
BioGanix, we compete not only with widely advertised branded products, but also with private
label products.
The Company’s management, combined with the support of the members of its Board of
Directors and Advisory Board, has access to strong innovation capabilities and has established
access to high-quality manufacturing through the acquisition of BioGanix. Management
believes that it is well-positioned to capitalize on favorable long-term trends in the
nutraceutical market.
FINANCIAL HIGHLIGHTS FOR THE REPORTING PERIOD
During the nine-month period ended March 31, 2018 the Company consolidated the sales
revenues from its subsidiary BGX E-Health LLC, which holds and operates the acquired assets
from BioGanix.
Sales revenue were generated by the Bioganix® brand and totaled $3,157,644 for the reporting
period ($NIL in 2016), which generated a gross profit of $1,806,515 ($NIL in 2016). The gross
margin of 57% continues to remain stable and adjusted EBITDA for the brand remain positive at
25%.
On a global basis, the reporting period was marked by a period of preparation for market
expansion, which included investments (increased expenses) on initiatives to build brand
equity, expand geographically, launch of new products and build the operating team. The
investments included brand repositioning, restructuring marketing spend, purchasing operating
software and other value-added services. Additionally, the company incurred material non-cash
expenses such as share-based payments and accretion, all of which impacted the earnings for
the period.
The Company reported net and comprehensive losses of $1,787,985 ($566,070 in 2017) and
Adjusted Earnings Before Interest, Taxes and Amortization (Adjusted EBITDA – see table below)
totaling ($384,151) in the same period.
Adjusted EBITDA
Net Loss -$ 1,787,985
Share based payments $ 554,110
Interest on long-term debt $ 348,422
Acreeted interest $ 263,618
Acquisitions and Related Costs $ 237,684
Adjusted EBITDA -$ 384,151
*Adjusted EBITDA and Non-IFRS Financial Measures
This MD&A includes certain measures which are not defined terms in accordance with IFRS
such as Adjusted EBITDA. The Term “Adjusted EBITDA” refers to net income (loss) after
adjusting for interest, taxes, depreciation and costs relating to acquisitions and their
integration.
The Company believes that Adjusted EBITDA is useful supplemental information as it provides
an indication of the results generated by the company’s main business activities prior to taking
into consideration how those activities are financed and taxed and prior to taking into
consideration depreciation and particularly the costs of integration of acquisitions.
Adjusted EBITDA is a key measure used by Management and the Company’s Board of Directors
(“Board”) to understand and evaluate the company’s operating performance, to prepare annual
budgets, and to help develop Operating Plans. Adjusted EBITDA is not a measure of
performance under IFRS and should not be considered in isolation or as a substitute for net and
comprehensive income (loss) prepared in accordance with IFRS or as a measure of operating
performance or profitability.
Adjusted EBITDA does not have a standardized meaning prescribed by IFRS and is not
necessarily comparable to similar measures presented by other companies.
OUTLOOK
The Company will continue to pursue the acquisition of e-retail brands, businesses and
technologies in the Health and Wellness market. As part of the overall acquisition strategy,
Relevium will invest in optimizing and developing the acquired e-brands and business following
a business model that includes:
• Optimization of its marketing and product positioning strategies
• Overview of its current product line and launching of new products
• Creation and launch new brands and product segments
• Obtaining licenses or direct sourcing of exclusive products
• Joint Ventures for market expansions
RESULTS FROM OPERATIONS
The reader of this MD&A and accompanying interim financial statements should be aware that
in the comparable periods for the three and nine months ended March 31, 2017, the Company
did not have an operating business. The consolidation of the financial statements of BGX EHealth
LLC (BioGanix) results in a completely different profile of both, revenues and expenses.
Nine months ended March 31, 2018
The following table summarizes financial results the six months ended March 31, 2018
Nine-months
ended March
31, 2018
Ninemonths
ended
March 31,
2017
Variance
Revenues 3,157,644 - 3,157,644
COGS 1,351,129 - 1,351,129
Gross Profit 1,806,515 - 1,806,515
Expenses -
Administration fees 287,248 112,700 174,548
Consulting Fees 308,067 165,438 142,629
General and administrative expenses 430,580 157,419 273,161
Selling and Marketing 1,252,668 - 1,252,668
Professional Fees 166,818 42,400 124,418
Share-based payments 554,110 14,638 539,472
Loss(gain) on foreign exchange (20,184) 1,179 (21,363)
Amortization expense 3,178 72,321 (69,143)
Interest and accretion 612,040 - 612,040
Net loss and comprehensive loss (1,787,985) (566,070) (1,221,915)
Adjusted EBITDA* (384,151) (477,932) 93,781
*Adusted EBITDA is a non-IFRS Financial Measure of Performance
During the nine-month period ended March 31, 2018, the Company’s focused primarily on the
integration of the activities of the BioGanix brand, business valuations and diligence in terms of
acquisitions development.
The company produced total revenues of $3,157,644 ($NIL in 2017) arising from direct to
consumer sales of nutraceutical products through the company’s various online platforms. Cost
of goods sold for the reporting period totaled $1,351,129 ($NIL in 2017), primarily composed of
the cost of finished products, warehousing and logistics, resulting in a gross profit of $1,806,515
(NIL in 2017) or a gross profit margin of 57% as compared to sales.
Total expenses for the reporting period were $3,594,524 ($566,095 in 2017) representing a
dollar value increase of $3,028,454, which resulted primarily from new expense categories
associated with the consolidation of the acquired business, the service of the debt incurred to
finance the acquisition and non-cash share-based compensation grants.
The company reported administration fees of $287,248 ($112,700 in 2017), consulting fees of
$308,067 ($165,438 in 2017), general and administrative expenses of $430,580 ($157,419 in
2017) and professional fees of $166,818 ($42,400 in 2017) all associated with the change in
business structure, hiring of key personnel and costs associated transition services, technology
development and due diligence.
The Company reported selling and marketing expenses of $1,252,668 ($NIL in 2017),
representing primarily the costs of operating the company’s e-commerce platforms including
Amazon and Shopify. The nature of these expenses includes commissions, advertising,
promotional campaigns and paid traffic, all costs that did not exist in the comparable period.
During the reporting period, the Company issued stock-based compensation to management,
directors and consultants resulting in a non-cash expense of $554,110 ($14,638 in 2017). This is
the company’s second issuance of stock options for directors and officers since it began trading
in August 2015.
The Company reported interest on long-term debt of $348,422 (NIL in 2017) and accreted
interest of $263,618 (NIL in 2017). The Company had a gain from foreign exchange of $20,184
(Loss of $1,179 in 2017).
As a result of the operations of the company for the nine-month period ended March 31, 2018,
the company reported a net loss and comprehensive loss of $1,787,985 ($566,070 in 2017).
Three months ended March 31, 2018
The following table summarizes financial results the three months ended March 31, 2018
Quarter
ended
March 31,
2018
Quarter
ended
March 31,
2017
Variance
Revenues 1,036,176 - 1,036,176
COGS 460,681 - 460,681
Gross Profit 575,495 - 575,495
Expenses
Administration fees 98,849 36,000 62,849
Consulting Fees 107,732 49,500 58,232
General and administrative expenses 186,489 79,217 107,272
Selling and Marketing 584,796 - 584,796
Professional Fees 85,921 18,246 67,675
Share-based payments - 3,698 (3,698)
Loss(gain) on foreign exchange 56,577 (331) 56,908
Amortization expense 2,119 24,107 (21,988)
Interest and accretion 208,656 - 208,656
Net loss and comprehensive loss (755,644) (210,437) (545,207)
Adjusted EBITDA* (292,517) (182,963) (109,554)
*Adusted EBITDA is a non-IFRS Financial Measure of Performance
During the three-month period ended March 31, 2018, the Company’s focused primarily on the
optimization and integration of the activities of the BioGanix brand, business valuations and
diligence in terms of acquisitions development.
The company produced total revenues of $1,036,176 ($NIL in 2017) arising from direct to
consumer sales of nutraceutical products through the company’s various online platforms. As
compared to the first quarter ended September 30, 2017, the revenues were slightly down
primarily the result of a 30-day disruption in the payment gateway in the Shopify marketplace,
product mix adjustments and minor seasonality.
Cost of goods sold for the reporting period totaled $460,681 ($NIL in 2017), primarily composed
of the cost of finished products, warehousing and logistics, resulting in a gross profit of
$575,495 (NIL in 2017) or a gross profit margin of 56% as compared to sales.
Total expenses for the reporting period were $1,331,139 ($210,437 in 2017) representing a
dollar value increase of $1,120,702, which resulted primarily from new expense categories
associated with the consolidation of the acquired business, the service of the debt incurred to
finance the acquisition, accreted interest and non-cash share-based compensation grants.
The company reported administration fees of $98,849 ($36,000 in 2017), consulting fees of
$107,732 ($49,500 in 2017), general and administrative expenses of $186,489 ($79,217 in 2017)
and professional fees of $85,921 ($18,246 in 2017) all associated with the change in business
structure, hiring of key personnel and costs associated transition services, technology
development and due diligence.
The Company reported selling and marketing expenses of $584,796 ($NIL in 2017), representing
primarily the costs of operating the company’s e-commerce platforms including Amazon and
Shopify. The nature of these expenses includes commissions, advertising, promotional
campaigns and paid traffic, all costs that did not exist in the comparable period.
The Company reported interest on long-term debt of $132,691 (NIL in 2017) and accreted
interest of $75,965 (NIL in 2017). The Company had a loss from foreign exchange of $56,577
(gain of $331 in 2017).
As a result of the operations of the company for the three-month period ended March 31,
2018, the company reported a net loss and comprehensive loss of $755,644 ($210,437 in 2017).
SUMMARY OF QUARTERLY RESULTS
Quarter Ended Revenues
Net &
comprehensive
lossfor the
period
Net loss per
share (Basic &
Diluted)
Weighted
average
common shares
March 31, 2018 1,036,176 755,644 0.00087 86,363,372
December 31, 2017 968,474 904,565 0.013 69,824,611
September 31, 2017 1,152,994 127,776 0.0019 65,971,466
June 30, 2017 NIL 2,018,668 0.055 35,918,448
March 31, 2017 NIL 210,437 0.0061 34,743,966
December 31, 2016 NIL 164,966 0.0048 34,582,966
September 31, 2016 NIL 190,667 0.006 31,886,367
June 30, 2016 NIL 684,198 0.0248 27,637,653
FINANCIAL POSITION
During the reporting period, which was also a period of integration, the Company continued to
deliver stable and growing sales revenues of $3,157,644 ($NIL in 2017) and a net and
comprehensive loss of $1,787,985 ($566,070 in 2017). As at March 31, 2018, the Company
reported cash and cash equivalents totaling $1,521,654 ($904,603 in June 30, 2017).
On July 2017, the Company obtained control over the assets purchased under the purchase
agreement for the acquisition of the assets of BioGanix.
31-mars-18 30-juin-17
$ $
Total Assets 8 158 384 7 115 152
Current Assets 2 332 699 1 038 452
Current Liabilities 1 166 245 1 285 690
Working Capital* 1 166 454 -247 238
*Working capital is defined as current assets less current liabilities.
For the nine-month period ended March 31, 2018, the company reported negative cash flows
from operations totaling $1,498,117 ($450,107 in 2017) primarily the result of increases in noncash
working capital items non-existing prior to the acquisition of BioGanix, including an
increase in accounts receivable of $134,776, increase in inventories of $468,687, increases in
prepaid expenses of $73,733 and decrease of accrued liabilities of $110,537
As at March 31, 2018 the company reported negative cash flows from investing activities of
$21,158 ($25 in 2017) for the purchase of office equipment.
As at March 31, 2018 the company reported positive cash flows from financing activities of
$2,136,351 ($520,025 in 2017) arising primarily from the exercise of incentive stock options and
share purchase warrants of $2,023,704 ($40,000 in 2017), the settlement of subscriptions
receivable of $60,000 ($NIL in 2017), the issue of a short term loan payable of $375,780 ($NIL in
2016), the repayment of long term debt of $25,380 ($23,775 in 2017), the repayment of
contingent consideration payable of $145,714 ($NIL in 2016) and the repayment of the shortterm
loan payable of $152,039 ($NIL in 2017).
The Company’s only significant source of funding has been the issuance of equity securities for
cash and debt financing. The acquisition of BioGanix has changed the status of the company,
from a developing stage company to an operating company with revenues and earnings, with
adjusted negative EBITDA of $384,515 (negative EBITDA $477,932 in 2017). The company
expects to continue to require funding from the capital markets to execute its ongoing
acquisitions strategy.
As at March 31, 2018 the Company had 27,322,354 warrants issued and outstanding that if fully
exercised, could generate $4,032,779 (27,322,354 warrants x $0.1476) in capital to support the
Company’s activities.
Number of warrants Exercise price $ Expiry Date
6,383,355 $0.15 Aug-18
1,722,500 $0.11 Aug-19
13,803,500 $0.15 Jun-19
3,913,000 $0.15 Aug-19
1,499,999 $0.15 Dec-19
27,322,354 $0.1476
Management also recognizes that capital markets are always in flux and there may be risks
involved beyond its control in securing additional capital or having outstanding warrants
exercised (See Going Concern Note)
CAPITAL RESOURCES
The Company’s objective is to maintain a strong capital base to maintain investor, creditor and
market confidence and to sustain future development of the business.
Management defines capital as the Company’s shareholders’ equity and long-term debt. The
Company’s only significant source of funding has been the issuance of equity securities for cash
and debt financing. The acquisition of BioGanix and subsequent acquisitions are expected to
change the status of the company, from non-revenue to a cash generating business.
The Company’s business model also includes the role of a consolidator in the nutraceutical ecommerce
space and such the Company expects to continue to make acquisitions in this space
through the capital markets.
OFF-BALANCE SHEET ARRANGEMENTS
The Company did not have any off-balance sheet transactions as at March 31, 2018.
RELATED PARTIES TRANSACTIONS
During the reporting period the following transactions occurred:
Consulting fees include $20,245 (2017 - $NIL) paid to a director of the Company.
Administration fees include directors fees of $10,500 (2017 – $NIL).
Professional fees include $58,177 of services provided by the legal secretary. The
company entered into an agreement with the legal secretary to issue shares in
exchange for services rendered in this capacity. The number shares to be issued is to
be determined using a value weighted price determination in exchange for the value of
the services received.
These transactions are measured at the exchange amount, which is the amount of
consideration determined and agreed to by the related parties. As at March 31, 2018, the
balance due to related parties amounted to $20,107.
BIOGANIX LTD ASSET ACQUISITION
On July 4, 2017, the Company completed its acquisition of certain assets of BioGanix LTD in
exchange for cash consideration in the amount of $1,900,000, the issuance of 6,750,000
common shares of the Company at the price of Cdn $0.13 per share which represents the fair
value of the shares issued, $500,000 as a performance based contingent consideration payable
in cash on December 31, 2017 and $1,550,000 in the form of a two-year convertible note
bearing interest at the rate of 8% payable quarterly. The convertible note allows the holder to
convert the principal amount, after an initial period of 12 months, into common shares of the
Company at an exercise price of Cdn$0.1396. as described in Note 11 of the condensed
consolidated interim financial statements.
The fair values of the acquired assets have been determined on a provisional basis pending the
completion of a formal valuation and have been allocated as follows:
$
Inventory 269,020
Trademarks and other intangible assets 2,555,692
Goodwill 3,251,988
6,076,700
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The preparation of financial statements in conformity with IFRS requires management to make
estimates and assumptions that affect amounts reported in financial statements and
accompanying notes. There is a full description and a detailed presentation of the Corporation’s
critical accounting policies, accounting judgments and uncertainties relative to significant
estimates are provided in the audited financial statements as at June 30, 2017.
OUTSTANDING SHARE DATA
The following information sets out the outstanding share data of the Company as at March 31,
2018:
Common shares issued Number of shares Amount
Balance as at June 30, 2017 65 971 466 $ 5 119 909
Balance as at March 31, 2018 87 079 063 $ 8 392 355
As of March 31, 2018, the Company had 87,079,063 common shares issued of which
2,359,125 of the issued and outstanding shares were subject to escrow conditions. The
company also has a total of 27,322,354 warrants issued.
On December 22, 2017, the Company amended its incentive stock option plan to increase the
maximum number of common shares issuable from 3,838,847 to 6,983,684. As at March 31,
2018, 4,432,800 options were issued and exercisable.
SUBSEQUENT EVENTS
Subsequent to March 31, 2018, the following events occurred:
On April 5, 2018 the Company announced that it has started the process of establishing
European presence for the new Bioganix® brand in partnership with several online partners,
including Amazon. The Company targets doing an initial launch of eight best-selling products,
which will be live online on the week of the May 21, 2018 with full marketing launch by midsummer.
On April 19, 2018 the Company announced the creation of Biocannabix Health Corporation (the
“Subsidiary” or “BHC”), a Canadian wholly owned subsidiary structured to lead the
development of the legal cannabis derivatives business for RLV. The Company projects to
complete its ACMPR application for the Canadian marketplace within the current fiscal quarter
and has begun to assemble its legal and regulatory team of experts within targeted
jurisdictions.
On April 26, 2018 the Company announced the creation of its two first cannabis brands,
LeefyLyfe and Biocannabix offering cannabis products in the North-American and European
markets. LeefyLyfe and Biocannabix brands are part of the wholly owned Biocannabix Health
Corporation (the “Subsidiary” or “BHC”).
On April 30, 2018 the Company announced the signing of a product development, supply and
commercialization agreement with Neptune Wellness Solutions (TSX:NEPT) (NASDAQ:NEPT) for
MaxSimil®, a patented fish oil monoglyceride omega 3 technology.
On May 3, 2018 the Company announced that it has received approval to sell its biggest mover
Bioganix® products on Walmart.com.
On behalf of the Board of Directors, we thank our shareholders for their continued support.
“Aurelio Useche”
Aurelio Useche
Chief Executive Officer
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
dorado
4年前
JackAskSlap
5年前
greenwillow
6年前
slickinvest
6年前
Hercules1
6年前
MADDSTACKER
6年前
MERCURIAL
6年前
MrCheap
6年前
